BAYER AG

Bayer's Eylea showed non-inferior visual acuity improvement in a phase III trial with 8 mg every 8 weeks vs. 2 mg every 4 weeks for retinal vein occlusion. This longer interval makes Eylea more attractive for patients needing eye injections, competing with Roche's Vabysmo.

The enzyme inhibitor market is projected to grow from US$2.8 Bn in 2023 to US$5.9 Bn by 2034, driven by applications in disease management, particularly cardiovascular diseases, oncology, and autoimmune disorders. Key drivers include advancements in monoclonal antibodies, RNA-based inhibitors, and oncology therapies. Major players like Merck & Co., Novartis AG, and Pfizer Inc. are investing in R&D and strategic partnerships to meet healthcare demands.

The global Epidermal Growth Factors (EGFs) market was valued at US$ 1.1 Bn in 2023 and is expected to grow at a CAGR of 11.3% to reach US$ 3.7 Bn by 2034, driven by applications in wound healing, cancer therapies, skincare, and regenerative medicine. Key drivers include rising demand for anti-aging products, advancements in biopharmaceutical research, increasing prevalence of chronic diseases, and strategic investments by companies like Thermo Fisher Scientific and Johnson & Johnson.

The CHMP recommended acoramidis, an oral TTR stabilizer, for EU marketing authorization in adult ATTR-CM patients. Acoramidis demonstrated near-complete TTR stabilization and benefits on cardiovascular endpoints in the ATTRibute-CM study. The CHMP's positive opinion offers hope for ATTR-CM patients, with a final EU decision expected soon.

The global Acute Myeloid Leukemia Therapeutics Market is projected to grow at a CAGR of 13.4% during 2024-2032, driven by advances in targeted therapies and immunotherapies.

Focke Ziemssen, Michelle Sylvanowicz, Winfried M. Amoaku, Tariq Aslam, Bora Eldem, Robert P. Finger, Richard P. Gale, Laurent Kodjikian, Jean-François Korobelnik, Xiaofeng Lin, Anat Loewenstein, Paul Mitchell, Moira Murphy, David R. Owens, Nick Parker, Ian Pearce, Francisco J. Rodríguez, Jude Stern, S. James Talks, David T. Wong, Tien Yin Wong, and Jane Barratt disclose various financial interests including travel grants, personal fees, advisory board memberships, speaker fees, research sponsorship, and consulting roles with companies such as Allergan, AbbVie, Alimera, Bayer Healthcare, Biogen, Boehringer Ingelheim, Janssen, Novartis, Novo Nordisk, Merck, Regeneron, Roche, Sanofi, and others.

Orly Vardeny discussed FINEARTS-HF trial findings on finerenone's efficacy in HF patients with EF ≥40%, reducing cardiovascular death and HF events. Finerenone shows kidney-protective effects and lower hyperkalemia risk than steroidal MRAs, though hyperkalemia incidence doubled. The trial supports finerenone's use alongside SGLT2 inhibitors, addressing HF treatment needs, with improvements in patient-reported functional status. Challenges remain in translating trial findings into clinical practice.

The CHMP recommended acoramidis, an orally administered TTR stabilizer, for EU marketing authorization in adult patients with ATTR-CM. Acoramidis demonstrated near-complete TTR stabilization and benefits on cardiovascular endpoints in the Phase III ATTRibute-CM study. The CHMP's positive opinion offers hope for ATTR-CM patients, with the European Commission's final decision expected soon. Bayer plans to launch acoramidis in Europe in the first half of 2025.

2024 saw significant medical advances, including FDA approval of Orlynvah for resistant UTIs, Cobenfy for schizophrenia, lenacapavir for HIV prevention, and Miplyffa/Aqneursa for Niemann-Pick disease type C. Elinzanetant showed promise for hot flashes, and future innovations include potential non-opioid pain treatments, improved flu vaccines, and gene therapy for vision restoration.

Bayer acquired HiDoc Technologies to commercialize Cara Care, a digital health app for IBS patients, offering personalized, guideline-compliant therapy modules, diet and psychotherapy support, and improved quality of life.